for up to 36 months [4] . These products are administered differently.
Retisert is surgically implanted into the posterior segment of the affected eye through a pars plana incision. ILUVIEN is an intravitreal implant that is inserted using a 25-gage needle into the vitreous cavity in the posterior eye with the optimal placement being inferior to the optic disc and posterior to the equator [2] . These products have different indications. In Europe, Retisert is not licensed whereas ILUVIEN is licensed and indicated for ''… the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies.'' [2] . In the USA, Retisert is indicated for ''…the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye'' [3] and not for DMO. 
